نتایج جستجو برای: آنتیبادی مونوکلونال trastuzumab

تعداد نتایج: 9324  

Journal: :International journal of oncology 2008
Sun Young Kim Hwang Phill Kim Yu Jung Kim Do Youn Oh Seock-Ah Im Dongsoon Lee Hyun-Soon Jong Tae-You Kim Yung-Jue Bang

HER2 has been found to be amplified in 10-20% of gastric cancers, and is correlated with poor outcome. The aims of this study were to recognize HER2 amplification in gastric cancer cell lines via fluorescence in situ hybridization and to evaluate the growth inhibitory effect of trastuzumab in HER2-amplified cell lines. To elucidate the mechanism of the growth inhibition, we performed cell cycle...

پایان نامه :وزارت علوم، تحقیقات و فناوری - دانشگاه اصفهان - دانشکده علوم 1390

پروتئین سبز فلورسنت green fluorescent protein (gfp)، پروتئینی با وزن مولکولی kda 27 شامل 238 اسیدآمینه و دارای ساختار فضایی بشکه ی ? می باشد که برای اولین بار در سال 1962 از ستاره ی دریاییaequorea victoria جداسازی شد. این پروتئین به دنبال تحریک با نور آبی، فلورسنس سبز ساطع کرده و این ویژگی باعث شده تا gfp به عنوان نشانگر برای بیان پروتئین های نوترکیب، گزارشگر برای بیان ژن و به عنوان برچسب برای ...

2011
Marina Mantzourani Helen Gogas Aikaterini Katsandris John Meletis

BACKGROUND Trastuzumab is a humanized, monoclonal antibody that interferes with the HER2/neu receptor and binds selectively to the HERB2 protein which causes uncontrolled proliferation of malignant breast cells. CASE REPORT We report a case of severe thrombocytopenia related to trastuzumab administration. Three days after the first dose of single-agent trastuzumab, the patient was admitted to...

2015
Barış Kılıçaslan Öner Özdoğan Gönül Demir Pişkin Nihan Kahya Eren Hüseyin Dursun

OBJECTIVE Left ventricular (LV) dysfunction after trastuzumab treatment in erb-2 breast cancer cases has been fully investigated. However, there is not enough data about the effect of trastuzumab treatment on right ventricular (RV) functions. This study is designed to evaluate the right heart changes by performing echocardiography after trastuzumab treatment in patients with erb-2 breast cancer...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2008
Yoshiki Katsumi Yasumichi Kuwahara Shinichi Tamura Ken Kikuchi Osamu Otabe Kunihiko Tsuchiya Tomoko Iehara Hiroshi Kuroda Hajime Hosoi Tohru Sugimoto

PURPOSE Malignant rhabdoid tumor (MRT) is an early childhood cancer with poor prognosis. Trastuzumab, a humanized monoclonal antibody against human epidermal growth factor receptor-2 (HER-2), has been shown to be effective against breast cancer and other cancers. We investigated the effect of trastuzumab on MRT cell lines. EXPERIMENTAL DESIGN We examined expression of HER-2 on four MRT cell l...

2016
U Weissenstein M Kunz K Urech U Regueiro S Baumgartner

BACKGROUND Besides conventional anticancer therapy many breast cancer patients use complementary and alternative medicine (CAM) like the medicinal herb mistletoe (Viscum album L.). To gain more knowledge about possible herb-drug interactions between CAM and conventional anticancer medications, in the present in vitro study we investigated the effect of a standardized mistletoe preparation on th...

2013
Xi Chen Han Wang Xue-nong Ou-yang Fang-wei Xie Jing-jing Wu

AIM OF THE STUDY To discuss the activation of the signal transduction pathway of phosphatidylinositol 3'-kinase/serine-threonine kinase (PI3K/Akt), one of the important targets of drug resistance of trastuzumab, which provides a theoretical basis for the targeted therapy of drug resistance of trastuzumab in breast cancer. MATERIAL AND METHODS Establish the drug-resistance sub-strain BT-HerR o...

2012
Takehiro Ichikawa Fumiaki Sato Kazuya Terasawa Soken Tsuchiya Masakazu Toi Gozoh Tsujimoto Kazuharu Shimizu

OBJECTIVE Trastuzumab has been used for the treatment of HER2-positive breast cancer (BC). However, a subset of BC patients exhibited resistance to trastuzumab therapy. Thus, clarifying the molecular mechanism of trastuzumab treatment will be beneficial to improve the treatment of HER2-positive BC patients. In this study, we identified trastuzumab-responsive microRNAs that are involved in the t...

2017
Tatsuaki Takeda Hiromasa Yamamoto Hirotaka Kanzaki Ken Suzawa Takahiro Yoshioka Shuta Tomida Xiaojiang Cui Ramachandran Murali Kei Namba Hiroki Sato Hidejiro Torigoe Mototsugu Watanabe Kazuhiko Shien Junichi Soh Hiroaki Asano Kazunori Tsukuda Yoshihisa Kitamura Shinichiro Miyoshi Toshiaki Sendo Shinichi Toyooka

BACKGROUND Overexpression of human epidermal growth factor receptor 2 (HER2) is observed in approximately 15-23% of breast cancers and these cancers are classified as HER2-positive breast cancer. Trastuzumab is the first-line targeted therapeutic drug for HER2-positive breast cancer and has improved patient overall survival. However, acquired resistance to trastuzumab is still a critical issue ...

2016
YUAN-YUAN CHEN LIN-WEI WANG FANG-FANG CHEN BI-BO WU BIN XIONG

Trastuzumab has been demonstrated to be an effective treatment in patients with human epidermal growth factor receptor-2 (HER-2) positive breast cancer (BC); however, inconsistent results with regards to the long-term survival benefits, safety and optimal administration timing of trastuzumab exist. The present meta-analysis investigated these inconsistencies in patients with HER-2 positive BC t...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید